Keywords: مهار کننده DPP-4; DPP-4 inhibitors; Dumping syndrome; GLP-1;
مقالات ISI مهار کننده DPP-4 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده DPP-4; Chronic kidney disease; GLP-1 receptor agonists; DPP-4 inhibitors; SGLT-2 inhibitors; Diabetes mellitus;
Keywords: مهار کننده DPP-4; blood pressure; diabetic kidney disease; DPP-4 inhibitors; GLP-1R agonists; glycemia; SGLT2 inhibitors; pression artérielle; néphropathie diabétique; inhibiteurs de la DPP-4; agonistes des récepteurs GLP-1; glycémie; inhibiteurs du SGLT2;
Keywords: مهار کننده DPP-4; Acute myocardial infarction; Diabetes mellitus; DPP-4 inhibitors; Sulfonylureas;
Keywords: مهار کننده DPP-4; GLP-1 receptor agonists; DPP-4 inhibitors; incretin therapy; primary care; type 2 diabetes mellitus;
Keywords: مهار کننده DPP-4; baseline characteristics; DPP-4 inhibitors; personalized medicine; SGLT2 inhibitors; type 2 diabetes;
Keywords: مهار کننده DPP-4; Type 1 diabetes; Type 2 diabetes; Diabetic nephropathy; DPP-4 inhibitors; SGLT2 inhibitors; Hyperfiltration;
Keywords: مهار کننده DPP-4; Diabetes mellitus; Metformin; TZDs; Incretins; DPP-4 inhibitors; SGLT2 inhibitors;
Keywords: مهار کننده DPP-4; Diabetes mellitus; GLP-1 receptor agonists; DPP-4 inhibitors; SGLT2 inhibitors; Insulin;
Keywords: مهار کننده DPP-4; Sitagliptin; Sulfonylurea; Albuminuria; DPP-4 inhibitors; Nephropathy;
Keywords: مهار کننده DPP-4; Diabetes mellitus; Cardiovascular; Heart failure; Prognosis; DPP-4 inhibitors;
Keywords: مهار کننده DPP-4; Mild dysglycemia; Type 2 diabetes; Post-prandial glucose; Dawn phenomenon; DPP-4 inhibitors;
Keywords: مهار کننده DPP-4; Diabetes mellitus; Cancer risk; Insulin; Antidiabetic drugs; ATP; adenosine triphosphate; BMI; body mass index; CI; confidence interval; DDDs; defined daily doses; DNA; deoxyribonucleic acid; DPP-4 inhibitors; dipeptidyl peptidase-4 inhibitors; Egr-1; ear
Keywords: مهار کننده DPP-4; Dipeptidyl peptidase 4; DPP-4 inhibitors; GLP-1 receptor agonists; Glucagon-like peptide 1; Incretin effect; Incretin mimetics; Pharmacotherapy;
Keywords: مهار کننده DPP-4; blood pressure; DPP-4 inhibitors; GLP-1; GLP-1R agonists; hypertension; incretins; type 2 diabetespression artérielle; inhibiteurs de la DPP-4; GLP-1; agonistes du GLP-1R; hypertension; incrétines; diabète de type 2
Worsening Heart Failure During the Use of DPP-4 Inhibitors
Keywords: مهار کننده DPP-4; diabetes; DPP-4 inhibitors; heart failure risk; saxagliptin; sitagliptin; AMP; adenosine monophosphate; DPP; dipeptidyl peptidase; GLP; glucagon-like peptide; SDF; stromal cell-derived factor; SGLT2; sodium-glucose transporter 2;
Prescription of DPP-4 Inhibitors to Patients With Adult Type 2 Diabetes Mellitus and Creatinine Clearance >50 mL/min: The UK Primary Care Experience
Keywords: مهار کننده DPP-4; dose selection; DPP-4 inhibitors; renal function; general practice; type 2 diabetes mellitus;
Recent updates on GLP-1 agonists: Current advancements & challenges
Keywords: مهار کننده DPP-4; Incretins; GLP-1 agonists; Type-2 diabetes mellitus; DPP-4 inhibitors;
Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential
Keywords: مهار کننده DPP-4; Stroke; Diabetes; DPP-4 inhibitors; GLP-1; Neuroprotection; GLP-1R agonists;
Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy
Keywords: مهار کننده DPP-4; Stroke; DPP-4 inhibitors; Type 2 diabetes mellitus;
Synthesis, pharmacological evaluation and molecular docking studies of pyrimidinedione based DPP-4 inhibitors as antidiabetic agents
Keywords: مهار کننده DPP-4; DPP-4 inhibitors; Drug design; GLIDE; Chemical structure; Pyrimidineiones; Molecular docking;
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Keywords: مهار کننده DPP-4; Glucagon-like peptide-1 (PubChem CID: 16135499); Sitagliptin (PubChem CID: 4369359); Vildagliptin (PubChem CID: 6918537); Saxagliptin (PubChem CID: 11243969); Linagliptin (PubChem CID: 10096344); Alogliptin (PubChem CID: 11450633); AKI; acute kidney injur
Quelle place reste-t-il pour les sulfamides hypoglycémiants dans la stratégie thérapeutique du diabète de type 2 ? Une place très réduite !
Keywords: مهار کننده DPP-4; Diabète de type 2; stratégie thérapeutique; controverse; sulfamides hypoglycémiants; inhibiteurs de la dipeptidyl peptidase 4; Type 2 diabetes; therapeutic strategy; controversy; sulfonylureas; DPP-4 inhibitors;
Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice
Keywords: مهار کننده DPP-4; Atherosclerosis; Perivascular adipose tissue; Inflammation; DPP-4 inhibitors; Endothelial function;
Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials
Keywords: مهار کننده DPP-4; DPP-4 inhibitors; Meta-analysis; Micro- and macrovascular complications; Mortality; Randomized clinical trials; Type 2 diabetes; CI; confidence interval; EXAMINE; Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; FDA; Food an
KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors
Keywords: مهار کننده DPP-4; KCNQ1; DPP-4 inhibitors; Pharmacogenetics; Type 2 diabetes;
Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor
Keywords: مهار کننده DPP-4; Quinazoline; Thiazoline; DPP-4 inhibitors; DPPH; Molecular docking;
Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists
Keywords: مهار کننده DPP-4; Cardiovascular disease; Clinical trial; DPP-4 inhibitors; GLP-1 receptor agonists; Mortality; Type 2 diabetes;
The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy
Keywords: مهار کننده DPP-4; New Pharmacovigilance legislation; Diabetes; Incretin-based therapy; DPP-4 inhibitors; Safety; Cardiovascular profile;
Brief ReportsFactors Contributing to the Clinical Effectiveness of the DPP-4 Inhibitor Sitagliptin in Patients With Type 2 Diabetes
Keywords: مهار کننده DPP-4; DPP-4 inhibitors; sitagliptin; sulfonylureas; type 2 diabetes mellitus;
Quelle place pour les nouveaux antidiabétiques dans la prise en charge du diabète du sujet âgé ?
Keywords: مهار کننده DPP-4; Diabète de type 2; sujet âgé; inhibiteurs de la DPP-4; agonistes du récepteur au GLP-1; inhibiteurs de SGLT-2; Type 2 diabetes; elderly subjects; DPP-4 inhibitors; GLP-1 receptor agonists; SGLT-2 inhibitors;
Profil des médecins prescripteurs des agonistes du récepteur du GLP-1 ou des inhibiteurs de la DPP4
Keywords: مهار کننده DPP-4; Diabète de type 2; traitement; incrétines; agonistes du récepteur du GLP-1; inhibiteurs de la DPP-4; caractéristiques des praticiens; déterminants des prescriptions; Type 2 diabetes; treatment; incretins; GLP-1 receptor agonists; DPP-4 inhibitors; ch
Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015
Keywords: مهار کننده DPP-4; Diabète de type 2; agonistes du récepteur du GLP-1; inhibiteurs de la DPP-4; traitement; sécurité cardiovasculaire; décompensation cardiaque; Type 2 diabetes; GLP-1 receptor agonists; DPP-4 inhibitors; treatment; cardiovascular safety; heart failure;
Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor – Teneligliptin in rats using liquid chromatography–tandem mass spectrometry
Keywords: مهار کننده DPP-4; Teneligliptin; DPP-4 inhibitors; Pharmacokinetics; Plasma protein binding; LC–MS; Ultra-filtration
Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis—A review
Keywords: مهار کننده DPP-4; DPP-4 inhibitors; Atherosclerosis; Cytokines; Diabetes
Le diabète de type 2 au stade de l'insuline : Quelle place pour les inhibiteurs de la DPP-4 ?
Keywords: مهار کننده DPP-4; Diabète de type 2; insuline; inhibiteurs de la DPP-4; hypoglycémie; insuffisance rénale; Type 2 diabetes; insulin; DPP-4 inhibitors; hypoglycemia; renal impairment;
Ãtude de la saxagliptine sur la survenue d'événements cardiovasculaires chez des patients diabétiques de type 2 (Ãtude SAVOR-TIMI 53) : les résultats
Keywords: مهار کننده DPP-4; Incrétines; prévention cardiovasculaire; inhibiteurs de la DPP-4; saxagliptine; Incretins; cardiovascular outcomes; DPP-4 inhibitors; saxagliptin;
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes
Keywords: مهار کننده DPP-4; China; DPP-4 inhibitors; Mixed-meal tolerance test; Saxagliptin; Type 2 diabetes mellitus
CommentaryNew Developments in Diabetes Management: Medications of the 21st Century
Keywords: مهار کننده DPP-4; Diabetes Treatment; Glucagon-like Peptide 1; DPP-4 inhibitors; Incretins; Sodium -glucose co transporter 2 (SGLT2) inhibition; Novel Insulins;
Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
Keywords: مهار کننده DPP-4; Meta-analysis; DPP-4 inhibitors; Heart failure
Ãtude HYPOCRAS : comparaison en vie réelle chez des patients âgés diabétiques de type 2 d'un traitement par inhibiteur de la DPP-4 versus autres antidiabétiques oraux en ajout à la metformine
Keywords: مهار کننده DPP-4; Diabète de type 2; sujet âgé; inhibiteurs de la DPP-4; antidiabétiques oraux; hypoglycémies.; Type 2 diabetes mellitus; elderly; DPP-4 inhibitors; oral antidiabetic agents; hypoglycemia.;
Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin
Keywords: مهار کننده DPP-4; DPP-4 inhibitors; Hybrid compound design; Linagliptin; Alogliptin; Diabetes
Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23)
Keywords: مهار کننده DPP-4; DPP-IV; Tetrahydropyran; DPP-4 inhibitors; Diabetes;
Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors
Keywords: مهار کننده DPP-4; DPP-4; CD26; DPP-4 inhibitors; Polyarthropathy; SDF-1α
Is there a place for incretin therapies in obesity and prediabetes?
Keywords: مهار کننده DPP-4; DPP-4 inhibitors; GLP-1 receptor agonists; glucose-dependent insulinotropic polypeptide; GIP; type 2 diabetes; appetite regulation; glucagon
Diabète de type 2, antidiabétiques oraux et complications cardiovasculaires
Keywords: مهار کننده DPP-4; Diabète de type 2; traitement; mortalité; complications cardiovasculaires; metformine; sulfonylurées; glinides; inhibiteurs des α-glucosidases intestinales; inhibiteurs de la DPP-4; analogues du GLP-1; revue générale; Type 2 diabetes mellitus; tre
Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No
Keywords: مهار کننده DPP-4; GLP-1 receptor agonists; DPP-4 inhibitors; Liraglutide; Exenatide; Sitagliptin
DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice β cells
Keywords: مهار کننده DPP-4; DPP-4; dipeptidyl peptidase-IV; CCD; charge-coupled device; ELISA; enzyme-linked immunosorbent assay; GFP; green fluorescent protein; KRB; Krebs ringer buffer; TIRF; total internal reflection fluorescence; TIRFM; TIRF microscopy; t-SNARE; target membrane
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Keywords: مهار کننده DPP-4; alogliptin; DPP-4 inhibitors; exenatide; GLP-1 receptor agonists; incretin therapies; liraglutide; saxagliptin; sitagliptin; type 2 diabetes; vildagliptin;
Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore
Keywords: مهار کننده DPP-4; Dipeptidyl peptidase 4; DPP-4; Dipeptidyl peptidase 4 inhibitors; DPP-4 inhibitors; 3-Amino-piperidine; (R)-3-Amino-3-methyl piperidine